Angiographic and clinical outcomes of STEMI patients treated with bioresorbable or metallic everolimus-eluting stents: A pooled analysis of individual patient data

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Standard

Angiographic and clinical outcomes of STEMI patients treated with bioresorbable or metallic everolimus-eluting stents : A pooled analysis of individual patient data. / Cassese, Salvatore; Katagiri, Yuki; Byrne, Robert A.; Brugaletta, Salvatore; Alfonso, Fernando; Räber, Lorenz; Maeng, Michael; Iniguez, Andres; Kretov, Evgeny; Onuma, Yoshinobu; Joner, Michael; Sabaté, Manel; Laugwitz, Karl Ludwig; Windecker, Stephan; Kastrati, Adnan; Serruys, Patrick W.

I: EuroIntervention, Bind 15, Nr. 16, 2020, s. 1451-1457.

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Harvard

Cassese, S, Katagiri, Y, Byrne, RA, Brugaletta, S, Alfonso, F, Räber, L, Maeng, M, Iniguez, A, Kretov, E, Onuma, Y, Joner, M, Sabaté, M, Laugwitz, KL, Windecker, S, Kastrati, A & Serruys, PW 2020, 'Angiographic and clinical outcomes of STEMI patients treated with bioresorbable or metallic everolimus-eluting stents: A pooled analysis of individual patient data', EuroIntervention, bind 15, nr. 16, s. 1451-1457. https://doi.org/10.4244/EIJ-D-18-01080

APA

Cassese, S., Katagiri, Y., Byrne, R. A., Brugaletta, S., Alfonso, F., Räber, L., Maeng, M., Iniguez, A., Kretov, E., Onuma, Y., Joner, M., Sabaté, M., Laugwitz, K. L., Windecker, S., Kastrati, A., & Serruys, P. W. (2020). Angiographic and clinical outcomes of STEMI patients treated with bioresorbable or metallic everolimus-eluting stents: A pooled analysis of individual patient data. EuroIntervention, 15(16), 1451-1457. https://doi.org/10.4244/EIJ-D-18-01080

CBE

Cassese S, Katagiri Y, Byrne RA, Brugaletta S, Alfonso F, Räber L, Maeng M, Iniguez A, Kretov E, Onuma Y, Joner M, Sabaté M, Laugwitz KL, Windecker S, Kastrati A, Serruys PW. 2020. Angiographic and clinical outcomes of STEMI patients treated with bioresorbable or metallic everolimus-eluting stents: A pooled analysis of individual patient data. EuroIntervention. 15(16):1451-1457. https://doi.org/10.4244/EIJ-D-18-01080

MLA

Vancouver

Author

Cassese, Salvatore ; Katagiri, Yuki ; Byrne, Robert A. ; Brugaletta, Salvatore ; Alfonso, Fernando ; Räber, Lorenz ; Maeng, Michael ; Iniguez, Andres ; Kretov, Evgeny ; Onuma, Yoshinobu ; Joner, Michael ; Sabaté, Manel ; Laugwitz, Karl Ludwig ; Windecker, Stephan ; Kastrati, Adnan ; Serruys, Patrick W. / Angiographic and clinical outcomes of STEMI patients treated with bioresorbable or metallic everolimus-eluting stents : A pooled analysis of individual patient data. I: EuroIntervention. 2020 ; Bind 15, Nr. 16. s. 1451-1457.

Bibtex

@article{d5ff7bd789474510b20bdf8e38f4ed15,
title = "Angiographic and clinical outcomes of STEMI patients treated with bioresorbable or metallic everolimus-eluting stents: A pooled analysis of individual patient data",
abstract = "Aims: Bioresorbable scaffolds (BRS) were conceived to ensure transient coronary artery support during antiproliferative drug delivery. However, the Absorb everolimus-eluting bioresorbable scaffold was found to be inferior to everolimus-eluting metallic stents (EES) in moderately complex coronary anatomies. We sought to investigate whether the Absorb represents a valuable option for the percutaneous treatment of patients with ST-elevation myocardial infarction (STEMI). Methods and results: We pooled the individual patient data of two randomised trials specifically designed to investigate the performance of Absorb versus EES in patients with acute myocardial infarction (MI). The primary outcome was lesion (in-segment) diameter stenosis at angiographic follow-up. The main secondary outcome was the device-oriented composite endpoint (DOCE) of cardiac death, target vessel MI and target lesion revascularisation at one year. A total of 388 patients with STEMI were allocated to Absorb (n=227) or EES (n=161). Angiographic follow-up at one year was available for 332 (85.6%) patients. Lesion diameter stenosis was comparable between Absorb and EES (22.8±9.8% versus 23.6±11.2%; mean difference -0.8%, 95% confidence interval [CI]: -3.18-1.48, p=0.47). DOCE occurred in 21 patients at one year, with similar distribution between the Absorb and EES groups (5.3% versus 5.6%; hazard ratio 0.95, 95% CI: 0.40-2.26, p=0.91). Conclusions: This pooled analysis provides evidence for a comparable angiographic performance and suggests similar clinical performance of Absorb and EES in STEMI patients undergoing percutaneous revascularisation. The long-term durability of Absorb and the extent to which newer BRS platforms might have a potential role in STEMI deserve further investigation.",
keywords = "Bioresorbable scaffolds, Drug-eluting stent, STEMI",
author = "Salvatore Cassese and Yuki Katagiri and Byrne, {Robert A.} and Salvatore Brugaletta and Fernando Alfonso and Lorenz R{\"a}ber and Michael Maeng and Andres Iniguez and Evgeny Kretov and Yoshinobu Onuma and Michael Joner and Manel Sabat{\'e} and Laugwitz, {Karl Ludwig} and Stephan Windecker and Adnan Kastrati and Serruys, {Patrick W.}",
year = "2020",
doi = "10.4244/EIJ-D-18-01080",
language = "English",
volume = "15",
pages = "1451--1457",
journal = "EuroIntervention",
issn = "1774-024X",
publisher = "Europa Digital & Publishing",
number = "16",

}

RIS

TY - JOUR

T1 - Angiographic and clinical outcomes of STEMI patients treated with bioresorbable or metallic everolimus-eluting stents

T2 - A pooled analysis of individual patient data

AU - Cassese, Salvatore

AU - Katagiri, Yuki

AU - Byrne, Robert A.

AU - Brugaletta, Salvatore

AU - Alfonso, Fernando

AU - Räber, Lorenz

AU - Maeng, Michael

AU - Iniguez, Andres

AU - Kretov, Evgeny

AU - Onuma, Yoshinobu

AU - Joner, Michael

AU - Sabaté, Manel

AU - Laugwitz, Karl Ludwig

AU - Windecker, Stephan

AU - Kastrati, Adnan

AU - Serruys, Patrick W.

PY - 2020

Y1 - 2020

N2 - Aims: Bioresorbable scaffolds (BRS) were conceived to ensure transient coronary artery support during antiproliferative drug delivery. However, the Absorb everolimus-eluting bioresorbable scaffold was found to be inferior to everolimus-eluting metallic stents (EES) in moderately complex coronary anatomies. We sought to investigate whether the Absorb represents a valuable option for the percutaneous treatment of patients with ST-elevation myocardial infarction (STEMI). Methods and results: We pooled the individual patient data of two randomised trials specifically designed to investigate the performance of Absorb versus EES in patients with acute myocardial infarction (MI). The primary outcome was lesion (in-segment) diameter stenosis at angiographic follow-up. The main secondary outcome was the device-oriented composite endpoint (DOCE) of cardiac death, target vessel MI and target lesion revascularisation at one year. A total of 388 patients with STEMI were allocated to Absorb (n=227) or EES (n=161). Angiographic follow-up at one year was available for 332 (85.6%) patients. Lesion diameter stenosis was comparable between Absorb and EES (22.8±9.8% versus 23.6±11.2%; mean difference -0.8%, 95% confidence interval [CI]: -3.18-1.48, p=0.47). DOCE occurred in 21 patients at one year, with similar distribution between the Absorb and EES groups (5.3% versus 5.6%; hazard ratio 0.95, 95% CI: 0.40-2.26, p=0.91). Conclusions: This pooled analysis provides evidence for a comparable angiographic performance and suggests similar clinical performance of Absorb and EES in STEMI patients undergoing percutaneous revascularisation. The long-term durability of Absorb and the extent to which newer BRS platforms might have a potential role in STEMI deserve further investigation.

AB - Aims: Bioresorbable scaffolds (BRS) were conceived to ensure transient coronary artery support during antiproliferative drug delivery. However, the Absorb everolimus-eluting bioresorbable scaffold was found to be inferior to everolimus-eluting metallic stents (EES) in moderately complex coronary anatomies. We sought to investigate whether the Absorb represents a valuable option for the percutaneous treatment of patients with ST-elevation myocardial infarction (STEMI). Methods and results: We pooled the individual patient data of two randomised trials specifically designed to investigate the performance of Absorb versus EES in patients with acute myocardial infarction (MI). The primary outcome was lesion (in-segment) diameter stenosis at angiographic follow-up. The main secondary outcome was the device-oriented composite endpoint (DOCE) of cardiac death, target vessel MI and target lesion revascularisation at one year. A total of 388 patients with STEMI were allocated to Absorb (n=227) or EES (n=161). Angiographic follow-up at one year was available for 332 (85.6%) patients. Lesion diameter stenosis was comparable between Absorb and EES (22.8±9.8% versus 23.6±11.2%; mean difference -0.8%, 95% confidence interval [CI]: -3.18-1.48, p=0.47). DOCE occurred in 21 patients at one year, with similar distribution between the Absorb and EES groups (5.3% versus 5.6%; hazard ratio 0.95, 95% CI: 0.40-2.26, p=0.91). Conclusions: This pooled analysis provides evidence for a comparable angiographic performance and suggests similar clinical performance of Absorb and EES in STEMI patients undergoing percutaneous revascularisation. The long-term durability of Absorb and the extent to which newer BRS platforms might have a potential role in STEMI deserve further investigation.

KW - Bioresorbable scaffolds

KW - Drug-eluting stent

KW - STEMI

UR - http://www.scopus.com/inward/record.url?scp=85083366532&partnerID=8YFLogxK

U2 - 10.4244/EIJ-D-18-01080

DO - 10.4244/EIJ-D-18-01080

M3 - Journal article

C2 - 30719976

AN - SCOPUS:85083366532

VL - 15

SP - 1451

EP - 1457

JO - EuroIntervention

JF - EuroIntervention

SN - 1774-024X

IS - 16

ER -